Transactions

Royalty Monetizations

Xoma

Royalty Monetization

$22 million

December 2016

North America

Opiant Pharmaceuticals

Partial Royalty Monetization

$17.5 million

December 2016

North America

IntelgenX

Partial Sale of Royalties and Milestones

$6 million

August 2016

North America

Selexis

Sale of a recombinant protein royalty portfolio to Ligand

April 2013

Europe

Undisclosed

Structured debt transaction linked to three pharma royalties

$65mm

December 2011

North America

Undisclosed

Sale of royalties by two private equity firms

July 2011

North America

Undisclosed

Sale of royalties to Cubicin and Lexiscan to Royalty Pharma

$487 million

April 2011

North America

Selexis

Sale of 15+ royalties on antibodies to Ligand

Selexis SA sold more then 15 biologic development programs to Ligand Pharmaceuticals Incorporated. The acquired programs are in various preclinical and clinical stages. Selexis intends to use the funds from the Ligand deal to conduct R&D to further develop the next generation of SUREtechnology Platform™ products. The Company’s SUREtechnology Platform™ is based on novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allows for higher and more stable expression of recombinant proteins. Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.

Press Release

Undisclosed

Sale of royalties to Cubicin and Lexiscan to Royalty Pharma

Royalty Pharma acquired the rights to certain royalties payable on sales of Lexiscan and Cubicin. Lexiscan is a market-leading pharmacologic stress agent for radionuclide myocardial perfusion imaging. Sales for the agent in the United States totaled $438 million. Cubicin is the first antibiotic in a class of anti-infectives called lipopeptides. The product posted U.S. sales of $600 million in 2010, which was 14% growth over the previous year. The acquisition deal was made in exchange for a cash payment of $487 million. Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property - principally royalty interests in marketed and late stage biopharmaceutical products.

Press Release